A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans.

Clinical studies have revealed that some fluoroquinolones may cause severe adverse effects when co-administered with substrates of CYP1A2. Our previous study showed antofloxacin (ATFX) was responsible for mechanism-based inhibition (MBI) of the metabolism of phenacetin in rats. In the clinical setting, ATFX is likely to be administrated with theophylline (TP), which is mainly metabolized by CYP1A2. The aim of the present study was to investigate the possible mechanism of TP/ATFX interaction. In vitro studies showed that the inhibitory effect of ATFX on the formation of three TP metabolites depended on NADPH, the pre-inhibition time, and ATFX concentration, i.e., factors which characterize MBI. In vivo studies demonstrated that single-dose ATFX (20 mg/kg) did not affect the pharmacokinetic behavior of TP, but multidose ATFX (20 mg/kg b.i.d. for 7.5 days) significantly increased the AUC of TP, decreased the amount of three TP metabolites in urine, and suppressed hepatic microsomal activity. A physiologically based pharmacokinetic (PBPK) model characterizing MBI of the three TP metabolites was developed for predicting TP/ATFX interaction in rats; this model was further extrapolated to humans. The predicted results were in good agreement with observed data. All the results indicated that ATFX was responsible for MBI of the metabolism of TP, and the PBPK model characterizing MBI may give good prediction of TP/ATFX interaction.

[1]  D. Breimer,et al.  Dose-dependent elimination of theophylline in rats. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  A. D. Rodrigues,et al.  Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  Ravi A. Desai,et al.  Decoupling diffusional from dimensional control of signaling in 3D culture reveals a role for myosin in tubulogenesis , 2010, Journal of Cell Science.

[4]  Jerome J. Schentag,et al.  Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. , 1987, The Journal of antimicrobial chemotherapy.

[5]  X. Liu,et al.  Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  T. Vree,et al.  ENOXACIN RAISES PLASMA THEOPHYLLINE CONCENTRATIONS , 1984, The Lancet.

[7]  A. Staib,et al.  Measurement of theophylline absorption from different regions of the gastro-intestinal tract using a remote controlled durg delivery device , 2004, European Journal of Clinical Pharmacology.

[8]  H. T. Karnes,et al.  In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes , 1990, Antimicrobial Agents and Chemotherapy.

[9]  K. Otani,et al.  Interaction Study Between Enoxacin and Fluvoxamine , 2005, Therapeutic drug monitoring.

[10]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[11]  Kiyomi Ito,et al.  Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes , 2004, Pharmaceutical Research.

[12]  F. Gonzalez,et al.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.

[13]  J. Miners,et al.  Differential effects of cimetidine on theophylline metabolic pathways , 2004, European Journal of Clinical Pharmacology.

[14]  Y. Sugiyama,et al.  Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  L. Paalzow,et al.  Pharmacokinetics of theophylline in relation to increased pain sensitivity in the rat , 1975, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  Sven Björkman,et al.  Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. , 2005, British journal of clinical pharmacology.

[17]  Y. Niki,et al.  Effects of DU-6859a, a New Quinolone Antimicrobial, on Theophylline Metabolism in In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.

[18]  Y. Sugiyama,et al.  Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4 , 2000, Pharmaceutical Research.

[19]  E. Kalso,et al.  Methadone, ciprofloxacin, and adverse drug reactions , 2000, The Lancet.

[20]  F. Leblond,et al.  Downregulation of hepatic cytochrome P450 in chronic renal failure. , 2001, Journal of the American Society of Nephrology : JASN.

[21]  D. Back,et al.  Theophylline metabolism in human liver microsomes: inhibition studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[22]  S. Jinnouchi,et al.  Prediction of plasma concentration-time curve of orally administered theophylline based on a scintigraphic monitoring of gastrointestinal transit in human volunteers. , 2002, International journal of pharmaceutics.

[23]  Y. Sugiyama,et al.  Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[25]  Jerome J. Schentag,et al.  The Quinolones: An Overview and Comparative Appraisal of Their Pharmacokinetics and Pharmacodynamics , 1988, Journal of clinical pharmacology.

[26]  M. G. Bilbao,et al.  Differential effects of leptin on ovarian metalloproteinases and their tissue inhibitors between in vivo and in vitro studies. , 2011, The Journal of endocrinology.

[27]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[28]  M. Monshouwer,et al.  Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Yong-hong Xiao,et al.  Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers , 2008, Biopharmaceutics & drug disposition.

[30]  Yonghong Xiao,et al.  A Phase II Study of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections , 2010, Chemotherapy.

[31]  R. Ogilvie.  Clinical Pharmacokinetics of Theophylline , 1978, Clinical pharmacokinetics.

[32]  E. J. Kim,et al.  Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. , 2003, Life sciences.

[33]  Guang-Ji Wang,et al.  Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. , 2003, Acta pharmacologica Sinica.

[34]  M. Fukaya,et al.  Acetic acid suppresses the increase in disaccharidase activity that occurs during culture of caco-2 cells. , 2000, The Journal of nutrition.

[35]  U. Fuhr,et al.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[36]  R. Vissing,et al.  Clinafloxacin-Theophylline Drug Interaction , 1995, The Annals of pharmacotherapy.

[37]  J. Wagner,et al.  The theophylline‐enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition , 1988, Clinical pharmacology and therapeutics.

[38]  R. Robson,et al.  Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. , 1990, British journal of clinical pharmacology.

[39]  J. Mackay-Dick.  Letter: Imported infections. , 1974, Lancet.

[40]  Sara K. Quinney,et al.  Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin , 2010, Drug Metabolism and Disposition.

[41]  Malcolm Rowland,et al.  Physiologic modeling of cyclosporin kinetics in rat and man , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[42]  S. Bowles,et al.  Inhibition of Drug Metabolism by Quinolone Antibiotics , 1988, Clinical pharmacokinetics.